<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1264" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1264/" /><meta name="ncbi_pagename" content="Andersen-Tawil Syndrome - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Andersen-Tawil Syndrome - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Andersen-Tawil Syndrome" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/06/07" /><meta name="citation_author" content="Aravindhan Veerapandiyan" /><meta name="citation_author" content="Jeffrey M Statland" /><meta name="citation_author" content="Rabi Tawil" /><meta name="citation_pmid" content="20301441" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1264/" /><meta name="citation_keywords" content="Long QT Syndrome Type 7 (LQTS Type 7)" /><meta name="citation_keywords" content="LQT7" /><meta name="citation_keywords" content="Long QT Syndrome Type 7" /><meta name="citation_keywords" content="LQTS Type 7" /><meta name="citation_keywords" content="G protein-activated inward rectifier potassium channel 4" /><meta name="citation_keywords" content="Inward rectifier potassium channel 2" /><meta name="citation_keywords" content="KCNJ2" /><meta name="citation_keywords" content="KCNJ5" /><meta name="citation_keywords" content="Andersen-Tawil Syndrome" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Andersen-Tawil Syndrome" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Aravindhan Veerapandiyan" /><meta name="DC.Contributor" content="Jeffrey M Statland" /><meta name="DC.Contributor" content="Rabi Tawil" /><meta name="DC.Date" content="2018/06/07" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1264/" /><meta name="description" content="Andersen-Tawil syndrome (ATS) is characterized by a triad of: episodic flaccid muscle weakness (i.e., periodic paralysis); ventricular arrhythmias and prolonged QT interval; and anomalies including low-set ears, widely spaced eyes, small mandible, fifth-digit clinodactyly, syndactyly, short stature, and scoliosis. Affected individuals present in the first or second decade with either cardiac symptoms (palpitations and/or syncope) or weakness that occurs spontaneously following prolonged rest or following rest after exertion. Mild permanent weakness is common. Mild learning difficulties and a distinct neurocognitive phenotype (i.e., deficits in executive function and abstract reasoning) have been described." /><meta name="og:title" content="Andersen-Tawil Syndrome" /><meta name="og:type" content="book" /><meta name="og:description" content="Andersen-Tawil syndrome (ATS) is characterized by a triad of: episodic flaccid muscle weakness (i.e., periodic paralysis); ventricular arrhythmias and prolonged QT interval; and anomalies including low-set ears, widely spaced eyes, small mandible, fifth-digit clinodactyly, syndactyly, short stature, and scoliosis. Affected individuals present in the first or second decade with either cardiac symptoms (palpitations and/or syncope) or weakness that occurs spontaneously following prolonged rest or following rest after exertion. Mild permanent weakness is common. Mild learning difficulties and a distinct neurocognitive phenotype (i.e., deficits in executive function and abstract reasoning) have been described." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1264/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/acpp/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1264/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B7E90E04268310000000001400073.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1264_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1264_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/als-overview/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/androgen/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1264_"><span class="title" itemprop="name">Andersen-Tawil Syndrome</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Long QT Syndrome Type 7 (LQTS Type 7)</div><p class="contrib-group"><span itemprop="author">Aravindhan Veerapandiyan</span>, MBBS, <span itemprop="author">Jeffrey M Statland</span>, MD, and <span itemprop="author">Rabi Tawil</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1264_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1264_ai__"><div class="contrib half_rhythm"><span itemprop="author">Aravindhan Veerapandiyan</span>, MBBS<div class="affiliation small">Department of Neurology<br />University of Rochester Medical Center<br />Rochester, New York<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.retsehcor.cmru@nayidnapareev_nahdnivara" class="oemail">ude.retsehcor.cmru@nayidnapareev_nahdnivara</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Jeffrey M Statland</span>, MD<div class="affiliation small">Department of Neurology<br />University of Kansas Medical Center<br />Kansas City, Kansas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.cmuk@dnaltatsj" class="oemail">ude.cmuk@dnaltatsj</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Rabi Tawil</span>, MD<div class="affiliation small">Department of Neurology<br />University of Rochester Medical Center<br />Rochester, New York<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.retsehcor.cmru@liwat_ibar" class="oemail">ude.retsehcor.cmru@liwat_ibar</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">November 22, 2004</span>; Last Update: <span itemprop="dateModified">June 7, 2018</span>.</p><p><em>Estimated reading time: 24 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="acpp.Summary" itemprop="description"><h2 id="_acpp_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Andersen-Tawil syndrome (ATS) is characterized by a triad of: episodic flaccid muscle weakness (i.e., periodic paralysis); ventricular arrhythmias and prolonged QT interval; and anomalies including low-set ears, widely spaced eyes, small mandible, fifth-digit clinodactyly, syndactyly, short stature, and scoliosis. Affected individuals present in the first or second decade with either cardiac symptoms (palpitations and/or syncope) or weakness that occurs spontaneously following prolonged rest or following rest after exertion. Mild permanent weakness is common. Mild learning difficulties and a distinct neurocognitive <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (i.e., deficits in executive function and abstract reasoning) have been described.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of ATS is established in an individual with characteristic clinical and ECG findings and/or identification of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KCNJ2</i>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations</i>: For episodic weakness: if serum potassium concentration is low (&#x0003c;3.0 mmol/L), administration of oral potassium (20-30 mEq/L) every 15-30 minutes (not to exceed 200 mEq in a 12-hour period) until the serum concentration normalizes; if a relative drop in serum potassium within the normal range causes episodic paralysis, an individual potassium replacement regimen with a goal of maintaining serum potassium levels in the high range of normal can be considered; if serum potassium concentration is high, ingesting carbohydrates may lower serum potassium levels. Mild exercise may shorten or reduce the severity of the attack.</p><p><i>Prevention of primary manifestations</i>: Reduction in frequency and severity of episodic attacks of weakness with lifestyle/dietary modification to avoid known triggers; use of carbonic anhydrase inhibitors; daily use of slow-release potassium supplements; implantable cardioverter-defibrillator for those with tachycardia-induced syncope. Empiric treatment with flecainide should be considered for significant, frequent ventricular arrhythmias in the setting of reduced left ventricular function.</p><p><i>Prevention of secondary complications</i>: Cautious use of antiarrhythmic drugs (particularly class I drugs) that may paradoxically exacerbate the neuromuscular symptoms.</p><p><i>Surveillance</i>: Annual screening of asymptomatic individuals with a <i>KCNJ2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> with a 12-lead ECG and 24-hour Holter monitoring.</p><p><i>Agents/circumstances to avoid</i>: Medications known to prolong QT intervals; salbutamol inhalers (may exacerbate cardiac arrhythmias); thiazide and other potassium-wasting diuretics (may provoke drug-induced hypokalemia and could aggravate the QT interval prolongation).</p><p><i>Evaluation of relatives at risk</i>: Molecular genetic testing if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is known; if not, detailed neurologic and cardiologic evaluation, 12-lead ECG, and 24-hour Holter monitoring to reduce morbidity and mortality through early diagnosis and treatment of at-risk relatives.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>ATS is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. At least 50% of individuals diagnosed with ATS have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Up to 50% of affected individuals have ATS as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Each child of an individual with ATS has a 50% chance of inheriting the disorder. Prenatal diagnosis for pregnancies at increased risk is possible if the <i>KCNJ2</i> pathogenic variant has been identified in an affected family member.</p></div></div><div id="acpp.Diagnosis"><h2 id="_acpp_Diagnosis_">Diagnosis</h2><div id="acpp.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Andersen-Tawil syndrome (ATS) <b>should be suspected</b> in individuals with <b>either</b> A <b>or</b> B:</p><dl class="temp-labeled-list"><dt>A.</dt><dd><p class="no_top_margin">Presence of two of the following three criteria:</p><ul><li class="half_rhythm"><div>Periodic paralysis</div></li><li class="half_rhythm"><div>Symptomatic cardiac arrhythmias or electrocardiographic evidence of enlarged U-waves, ventricular ectopy, or a prolonged QTc or QUc interval</div></li><li class="half_rhythm"><div>Characteristic facies, dental anomalies, small hands and feet, AND at least two of the following:</div><ul><li class="half_rhythm"><div>Low-set ears</div></li><li class="half_rhythm"><div>Widely spaced eyes</div></li><li class="half_rhythm"><div>Small mandible</div></li><li class="half_rhythm"><div>Fifth-digit clinodactyly</div></li><li class="half_rhythm"><div>Syndactyly of toes 2 and 3</div></li></ul></li></ul></dd><dt>B.</dt><dd><p class="no_top_margin">One of the above three criteria AND at least one other family member who meets two of the three criteria [<a class="bk_pop" href="#acpp.REF.statland.2018.522">Statland et al 2018</a>]</p></dd></dl></div><div id="acpp.Supportive_Findings"><h3>Supportive Findings</h3><p>Individuals with either episodic weakness or cardiac symptoms require careful evaluation by a neurologist and/or cardiologist as well as measurement of serum potassium concentration (baseline and during attacks of flaccid paralysis), a 12-lead ECG, a 24-hour Holter monitor, and possibly the long exercise protocol.</p><ul><li class="half_rhythm"><div><b>Serum potassium concentration</b> during episodes of weakness may be elevated, normal, or, most commonly, reduced (&#x0003c;3.5 mmol/U) [<a class="bk_pop" href="#acpp.REF.sansone.2007.233">Sansone &#x00026; Tawil 2007</a>, <a class="bk_pop" href="#acpp.REF.statland.2018.522">Statland et al 2018</a>].</div></li><li class="half_rhythm"><div><b>Routine nerve conduction electrophysiology</b> is normal between episodes. A more sensitive electrophysiologic study, the long exercise protocol, may reveal an immediate post-exercise increment followed by an abnormal decrement in the compound motor action potential amplitude (&#x0003e;40%) [<a class="bk_pop" href="#acpp.REF.katz.1999.352">Katz et al 1999</a>] or area (&#x0003e;50%) 20-40 minutes post exercise [<a class="bk_pop" href="#acpp.REF.kuntzer.2000.1089">Kuntzer et al 2000</a>, <a class="bk_pop" href="#acpp.REF.fournier.2004.650">Fournier et al 2004</a>]. In a study of 11 individuals with ATS, 82% met long-exercise amplitude decrement criteria for abnormal testing [<a class="bk_pop" href="#acpp.REF.tan.2011.328">Tan et al 2011</a>].</div></li><li class="half_rhythm"><div><b>Electrocardiogram</b> may reveal characteristic abnormalities including prominent U waves, prolonged Q-U intervals, premature ventricular contractions, polymorphic ventricular tachycardia, and bidirectional ventricular tachycardia [<a class="bk_pop" href="#acpp.REF.zhang.2005.2720">Zhang et al 2005</a>, <a class="bk_pop" href="#acpp.REF.delannoy.2013.1805">Delannoy et al 2013</a>, <a class="bk_pop" href="#acpp.REF.koppikar.2015.1493">Koppikar et al 2015</a>, <a class="bk_pop" href="#acpp.REF.statland.2018.522">Statland et al 2018</a>].</div></li><li class="half_rhythm"><div><b>24-hour Holter monitoring</b> is important to document the presence, frequency, and duration of ventricular tachycardia (VT) and the presence or absence of associated symptoms.</div></li></ul></div><div id="acpp.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of ATS <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the presence of A or B in <a href="#acpp.Suggestive_Findings">Suggestive Findings</a> and/or by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KCNJ2</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1264/table/acpp.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figacppTmoleculargenetictestingusedin" rid-ob="figobacppTmoleculargenetictestingusedin">Table 1</a>).</p><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (single-gene testing, <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) and <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of ATS is broad, individuals with the distinctive findings described in <a href="#acpp.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#acpp.Option_1">Option 1</a>), whereas those with a phenotype indistinguishable from many other inherited disorders with cardiac arrhythmias are more likely to be diagnosed using genomic testing (see <a href="#acpp.Option_2">Option 2</a>).</p><div id="acpp.Option_1"><h4>Option 1</h4><p>When the phenotypic and laboratory findings suggest the diagnosis of ATS <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications are not detected. Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>KCNJ2</i> first. If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found perform gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>KCNJ2</i> to detect intragenic deletions or duplications. If no <i>KCNJ2</i> pathogenic variant is found, perform sequence analysis of <i>KCNJ5</i> (see <a class="figpopup" href="/books/NBK1264/table/acpp.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figacppTmoleculargenetictestingusedin" rid-ob="figobacppTmoleculargenetictestingusedin">Table 1</a>, footnote 7).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>KCNJ2</i>, <i>KCNJ5</i>, and other genes of interest (see <a href="#acpp.Differential_Diagnosis">Differential Diagnosis</a> and <a href="/books/n/gene/rws/">Long QT Syndrome</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview.</i> (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul></div><div id="acpp.Option_2"><h4>Option 2</h4><p>When the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is indistinguishable from many other inherited disorders characterized by cardiac arrhythmias, <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="acpp.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Andersen-Tawil Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1264/table/acpp.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__acpp.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>KCNJ2</i></td><td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~70%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>KCNJ5</i></td><td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 7</td></tr><tr><td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown, none reported</td></tr><tr><td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~30%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="acpp.TF.1.1"><p class="no_margin">See <a href="/books/NBK1264/">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="acpp.TF.1.2"><p class="no_margin">See <a href="#acpp.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="acpp.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="acpp.TF.1.4"><p class="no_margin"><a class="bk_pop" href="#acpp.REF.plaster.2001.511">Plaster et al [2001]</a>, <a class="bk_pop" href="#acpp.REF.ai.2002.2592">Ai et al [2002]</a>, <a class="bk_pop" href="#acpp.REF.andelfinger.2002.663">Andelfinger et al [2002]</a>, <a class="bk_pop" href="#acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al [2002]</a>, <a class="bk_pop" href="#acpp.REF.donaldson.2003.1811">Donaldson et al [2003]</a>, <a class="bk_pop" href="#acpp.REF.hosaka.2003.409">Hosaka et al [2003]</a></p></div></dd><dt>5. </dt><dd><div id="acpp.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="acpp.TF.1.6"><p class="no_margin">Large deletions of <i>KCNJ2</i> are reported [<a class="bk_pop" href="#acpp.REF.lestner.2012.700">Lestner et al 2012</a>, <a class="bk_pop" href="#acpp.REF.vergult.2012.534">Vergult et al 2012</a>, <a class="bk_pop" href="#acpp.REF.marquisnicholson.2014.17">Marquis-Nicholson et al 2014</a>]. The prevalence of large deletions is unknown.</p></div></dd><dt>7. </dt><dd><div id="acpp.TF.1.7"><p class="no_margin">One individual with periodic paralysis, ventricular arrhythmias, no history of hypertension, and normal plasma aldosterone levels was found to have a <a class="figpopup" href="/books/NBK1264/table/acpp.T.kcnj2_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figacppTkcnj2pathogenicvariantsdiscuss" rid-ob="figobacppTkcnj2pathogenicvariantsdiscuss">p.Gly387Thr</a> variant in <i>KCNJ5.</i> Of individuals with suspected ATS in whom a <i>KCNJ2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was not identified, 1/21 had a <a class="figpopup" href="/books/NBK1264/table/acpp.T.kcnj2_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figacppTkcnj2pathogenicvariantsdiscuss" rid-ob="figobacppTkcnj2pathogenicvariantsdiscuss">p.Thr158Ala</a>
<i>KCNJ5</i> variant identified [<a class="bk_pop" href="#acpp.REF.kokunai.2014.1058">Kokunai et al 2014</a>].</p></div></dd></dl></div></div></div></div></div></div><div id="acpp.Clinical_Characteristics"><h2 id="_acpp_Clinical_Characteristics_">Clinical Characteristics</h2><div id="acpp.Clinical_Description"><h3>Clinical Description</h3><p>Andersen-Tawil syndrome (ATS) is characterized by a triad of features:</p><ul><li class="half_rhythm"><div>Episodic flaccid muscle weakness (periodic paralysis)</div></li><li class="half_rhythm"><div>Cardiac abnormalities (ventricular arrhythmias, prolonged QTc or QUc intervals, and prominent U waves)</div></li><li class="half_rhythm"><div>Distinctive <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> features</div></li></ul><p>Affected individuals present initially with either periodic paralysis or cardiac symptoms (palpitations and/or syncope) in the first or second decade [<a class="bk_pop" href="#acpp.REF.tawil.1994.326">Tawil et al 1994</a>, <a class="bk_pop" href="#acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</a>]; however, prospective standardized natural history data are not yet available. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is highly variable. The characteristic triad is present in 58%-78% of individuals with <i>KCNJ2</i> pathogenic variants [<a class="bk_pop" href="#acpp.REF.statland.2018.522">Statland et al 2018</a>].</p><p><b>Weakness.</b> Intermittent weakness occurs spontaneously, or alternatively may be triggered by prolonged rest or rest following exertion. The attack frequency, duration, and severity are variable between and within <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Mild permanent weakness is common [<a class="bk_pop" href="#acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</a>]. Affected individuals can develop fixed proximal weakness over time.</p><p><b>Ventricular arrhythmias</b> including bidirectional ventricular tachycardia (VT), polymorphic VT, and multifocal premature ventricular contractions may be asymptomatic, or may manifest (most commonly) as palpitations. Less common symptomatic presentations include syncope, cardiac arrest, or sudden death [<a class="bk_pop" href="#acpp.REF.andelfinger.2002.663">Andelfinger et al 2002</a>, <a class="bk_pop" href="#acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</a>, <a class="bk_pop" href="#acpp.REF.donaldson.2003.1811">Donaldson et al 2003</a>]. While the ECG may reveal a long QTc (LQT) interval, characteristic T-U patterns including enlarged U waves, a wide T-U junction, and prolonged terminal T-wave downslope distinguish ATS from other LQT syndromes [<a class="bk_pop" href="#acpp.REF.zhang.2005.2720">Zhang et al 2005</a>, <a class="bk_pop" href="#acpp.REF.haruna.2007.208">Haruna et al 2007</a>]. A large case series found no significant difference in the incidence of ventricular tachyarrhythmias between individuals with typical and atypical presentations of ATS [<a class="bk_pop" href="#acpp.REF.kimura.2012.344">Kimura et al 2012</a>]. A retrospective multicenter French study of 36 individuals with ATS followed for an average of 9.5 years reported no deaths in follow up; four individuals experienced syncope and one individual had a non-fatal cardiac arrest [<a class="bk_pop" href="#acpp.REF.delannoy.2013.1805">Delannoy et al 2013</a>].</p><p><b>Dilated cardiomyopathy</b> was observed in two of three <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in a single kindred with <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a href="#acpp.Treatment_of_Manifestations">p.Arg218Trp</a> [<a class="bk_pop" href="#acpp.REF.schoonderwoerd.2006.1346">Schoonderwoerd et al 2006</a>]. Additionally, cardiomyopathy was documented and reversed by treatment with flecainide in an individual with pathogenic variant <a class="figpopup" href="/books/NBK1264/table/acpp.T.kcnj2_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figacppTkcnj2pathogenicvariantsdiscuss" rid-ob="figobacppTkcnj2pathogenicvariantsdiscuss">p.Arg67Trp</a> [<a class="bk_pop" href="#acpp.REF.pellizz_n.2008.95">Pellizz&#x000f3;n et al 2008</a>], and reversed by bisoprolol in another individual with typical clinical features of ATS and novel variant <a class="figpopup" href="/books/NBK1264/table/acpp.T.kcnj2_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figacppTkcnj2pathogenicvariantsdiscuss" rid-ob="figobacppTkcnj2pathogenicvariantsdiscuss">p.Leu222Ser</a> [<a class="bk_pop" href="#acpp.REF.rezazadeh.2016.1576.e15">Rezazadeh et al 2016</a>]. These reports suggest that dilated cardiomyopathy is a secondary <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> as a consequence of chronic tachycardia rather than a primary phenotypic manifestation. Additional study is needed to further delineate this clinical feature.</p><p><b>Distinctive physical features</b> recognized initially included low-set ears, widely spaced eyes, small mandible, fifth-digit clinodactyly, second and third toe syndactyly, short stature, broad nasal root, and scoliosis [<a class="bk_pop" href="#acpp.REF.andersen.1971.559">Andersen et al 1971</a>, <a class="bk_pop" href="#acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</a>, <a class="bk_pop" href="#acpp.REF.donaldson.2003.1811">Donaldson et al 2003</a>]. Dental enamel discoloration was noted in two kindreds with the <a class="figpopup" href="/books/NBK1264/table/acpp.T.kcnj2_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figacppTkcnj2pathogenicvariantsdiscuss" rid-ob="figobacppTkcnj2pathogenicvariantsdiscuss">p.Gly300Asp</a> and <a class="figpopup" href="/books/NBK1264/table/acpp.T.kcnj2_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figacppTkcnj2pathogenicvariantsdiscuss" rid-ob="figobacppTkcnj2pathogenicvariantsdiscuss">p.Arg218Trp</a> pathogenic variants [<a class="bk_pop" href="#acpp.REF.davies.2005.1083">Davies et al 2005</a>].</p><p>Detailed, prospectively collected data in ten individuals with confirmed <i>KCNJ2</i> pathogenic variants have expanded the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> to include a characteristic facies and dental and skeletal anomalies [<a class="bk_pop" href="#acpp.REF.yoon.2006a.312">Yoon et al 2006a</a>].</p><ul><li class="half_rhythm"><div>Characteristic facies include broad forehead, short palpebral fissures, wide nasal bridge with bulbous nose, hypoplasia of maxilla and mandible, thin upper lip, and a triangular face.</div></li><li class="half_rhythm"><div>Dental findings include (among others) persistent primary dentition, multiple missing teeth (oligodontia), and dental crowding.</div></li><li class="half_rhythm"><div>Skeletal findings include mild syndactyly of toes two and three as well as fifth-digit clinodactyly.</div></li><li class="half_rhythm"><div>Novel findings include small hands and feet (&#x0003c;10th centile for age) and joint laxity.</div></li></ul><p>Note: Isolated reports of <b>renal anomalies</b> include unilateral hypoplastic kidney [<a class="bk_pop" href="#acpp.REF.andelfinger.2002.663">Andelfinger et al 2002</a>] and renal tubular defect [<a class="bk_pop" href="#acpp.REF.davies.2005.1083">Davies et al 2005</a>].</p><p><b>Mild learning difficulties</b> have been described [<a class="bk_pop" href="#acpp.REF.davies.2005.1083">Davies et al 2005</a>]. A distinct neurocognitive <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (i.e., deficits in executive function and abstract reasoning) has been recognized in individuals with a <i>KCNJ2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> despite IQ levels similar to those of their unaffected sibs [<a class="bk_pop" href="#acpp.REF.yoon.2006b.1703">Yoon et al 2006b</a>]. Growth restriction and developmental delay have been described as well [<a class="bk_pop" href="#acpp.REF.kim.2016.110">Kim et al 2016</a>].</p><p><b>Afebrile seizures</b> occurring only in infancy were reported in 4/23 (17%) of a Japanese cohort with molecularly confirmed ATS [<a class="bk_pop" href="#acpp.REF.haruna.2007.208">Haruna et al 2007</a>].</p></div><div id="acpp.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Whether a <i>KCNJ2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is present or not, individuals with clinically defined ATS are phenotypically indistinguishable [<a class="bk_pop" href="#acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</a>, <a class="bk_pop" href="#acpp.REF.donaldson.2003.1811">Donaldson et al 2003</a>].</p><p>In a case series that evaluated for <i>KCNJ2</i> pathogenic variants in individuals with typical (&#x0003e;2 ATS features) and atypical (only 1 ATS feature or catecholaminergic polymorphic ventricular tachycardia [CPVT]) features of ATS, the proportion of individuals with an identified <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was 75% (15/20) in those with typical ATS, 71% (5/7) in those with the cardiac <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> alone, 100% (2/2) in those with periodic paralysis, and 7% (2/28) in those with CPVT [<a class="bk_pop" href="#acpp.REF.kimura.2012.344">Kimura et al 2012</a>].</p><p>In a single large kindred with the <i>KCNJ2</i>
<a class="figpopup" href="/books/NBK1264/table/acpp.T.kcnj2_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figacppTkcnj2pathogenicvariantsdiscuss" rid-ob="figobacppTkcnj2pathogenicvariantsdiscuss">p.Arg67Trp</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, periodic paralysis was observed only in men, cardiac symptoms only in women, and <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> anomalies in both [<a class="bk_pop" href="#acpp.REF.andelfinger.2002.663">Andelfinger et al 2002</a>]. However, this apparent sex-limited bias in clinical presentation has not been confirmed [<a class="bk_pop" href="#acpp.REF.donaldson.2003.1811">Donaldson et al 2003</a>, <a class="bk_pop" href="#acpp.REF.davies.2005.1083">Davies et al 2005</a>].</p><p>A large five-generation family was found to have a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> in <i>KCNJ2</i> (<a class="figpopup" href="/books/NBK1264/table/acpp.T.kcnj2_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figacppTkcnj2pathogenicvariantsdiscuss" rid-ob="figobacppTkcnj2pathogenicvariantsdiscuss">c.271_282del12;p.Ala91_Leu94del</a>) and more severe cardiac manifestations, including 4/10 individuals receiving an implantable cardioverter-defibrillator and 5/10 reporting life-threatening ventricular arrhythmias in childhood [<a class="bk_pop" href="#acpp.REF.fernlund.2013.471">Fernlund et al 2013</a>]. These individuals had characteristic mild <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> features, but only one had periodic paralysis.</p><p>Two pathogenic variants in <i>KCNJ2</i> associated with a reduction in Kir2.1 current but without a <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> effect on normal channels (<a class="figpopup" href="/books/NBK1264/table/acpp.T.kcnj2_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figacppTkcnj2pathogenicvariantsdiscuss" rid-ob="figobacppTkcnj2pathogenicvariantsdiscuss">p.Asn318Ser</a> and <a class="figpopup" href="/books/NBK1264/table/acpp.T.kcnj2_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figacppTkcnj2pathogenicvariantsdiscuss" rid-ob="figobacppTkcnj2pathogenicvariantsdiscuss">p.Trp322Cys</a>) were described in three individuals with an <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> cardiac <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>: with premature ventricular contractions, ventricular tachycardia, or ventricular fibrillation [<a class="bk_pop" href="#acpp.REF.limberg.2013.353">Limberg et al 2013</a>].</p><p>A recent study examined the predictors of arrhythmias in 11 unrelated families with ATS (11 probands who were all female, 14 unaffected <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> family members with the <i>KCNJ2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, and 19 family members without the pathogenic variant) and found that a higher risk for arrhythmia, syncope, and/or cardiac arrest was associated with the presence of micrognathia, periodic paralysis, and prolonged duration of the descending portion of T-wave (T<sub>peak</sub> &#x02013; T<sub>end</sub> time) . It was also noted that the ATS clinical manifestations appeared to be more severe in females. The presence of a benign / <a class="def" href="/books/n/gene/glossary/def-item/likely-benign/">likely benign variant</a> in <i>KCNH2</i> appeared to be associated with a higher risk for syncope [<a class="bk_pop" href="#acpp.REF.krych.2017.504">Krych et al 2017</a>].</p></div><div id="acpp.Penetrance"><h3>Penetrance</h3><p>Non-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> is evident in 6%-20% of individuals with an identifiable <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#acpp.REF.andelfinger.2002.663">Andelfinger et al 2002</a>, <a class="bk_pop" href="#acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</a>, <a class="bk_pop" href="#acpp.REF.donaldson.2003.1811">Donaldson et al 2003</a>].</p></div><div id="acpp.Nomenclature"><h3>Nomenclature</h3><p>Although listed in OMIM, the following names for ATS are no longer in clinical use:</p><ul><li class="half_rhythm"><div>Periodic paralysis, potassium-sensitive cardiodysrhythmic type</div></li><li class="half_rhythm"><div>Andersen cardiodysrhythmic periodic paralysis</div></li></ul></div><div id="acpp.Prevalence"><h3>Prevalence</h3><p>The estimated prevalence of ATS is 0.08 &#x02013; 0.1 per 100,000 [<a class="bk_pop" href="#acpp.REF.horga.2013.1472">Horga et al 2013</a>, <a class="bk_pop" href="#acpp.REF.stunnenberg.2018.402">Stunnenberg et al 2018</a>].</p></div></div><div id="acpp.Genetically_Related_Allelic_Disorde"><h2 id="_acpp_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p><b>Familial atrial fibrillation 9</b> (OMIM <a href="https://omim.org/entry/613980" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613980</a>). A <i>KCNJ2</i> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant was described in a Chinese family; five <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and two individuals who did not have atrial fibrillation were identified to have the variant.</p><p><b>Short QT syndrome 3</b> (OMIM <a href="https://omim.org/entry/609622" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">609622</a>). A <i>KCNJ2</i> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant was identified in a female age five years and her father who had short QT intervals and asymmetric T waves on ECG. Pathogenic variants in <i>KCNH2</i> and <i>KCNQ1</i>, the two genes associated with short QT syndrome, were not identified.</p></div><div id="acpp.Differential_Diagnosis"><h2 id="_acpp_Differential_Diagnosis_">Differential Diagnosis</h2><p>Andersen-Tawil syndrome (ATS) should be considered in any individual presenting with periodic paralysis and ventricular arrhythmias or prominent U wave or prolonged QTc. Individuals with either episodic weakness or cardiac symptoms require careful evaluation by a neurologist and/or cardiologist as well as measurement of serum potassium concentration (baseline and during attacks of flaccid paralysis), a 12-lead ECG, a 24-hour Holter monitor, and possibly the long exercise protocol. The differential diagnosis depends on the initial presentation and includes the primary and secondary periodic paralyses, thyrotoxic periodic paralysis, and conditions associated with long QT.</p><div id="acpp.Episodes_of_Flaccid_Paralysis"><h3>Episodes of Flaccid Paralysis</h3><p><a href="/books/n/gene/hpp/">Hypokalemic periodic paralysis</a> is the most common periodic paralysis. Affected individuals may experience paralytic episodes with concomitant hypokalemia (&#x0003c;2.5 mmol/L), and occasionally may develop late-onset proximal myopathy. The paralytic attacks are characterized by reversible flaccid paralysis usually leading to paraparesis or tetraparesis but typically sparing the respiratory muscles and heart. The onset, duration, and severity of attacks, with the associated triggers, are similar to those in individuals with ATS. Weakness is improved with oral potassium ingestion. The cardiac and <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> features of ATS are, however, absent in individuals with hypokalemic periodic paralysis. Molecular testing identifies pathogenic variants in <i>CACNA1S</i> or <i>SCN4A</i> in approximately 80% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals after secondary causes such as thyrotoxicosis, diuretic use, and renal (e.g., hyperaldosteronism, distal tubular acidosis) or gastrointestinal (e.g., vomiting, diarrheal illness) causes have been ruled out. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</p><p><a href="/books/n/gene/hyper-pp/">Hyperkalemic periodic paralysis</a> is characterized by episodes of flaccid paralysis associated with normal or elevated ictal serum potassium concentrations (&#x0003e;5.0 mmol/U) and aggravated by potassium ingestion. Onset is in the first decade; episodes are briefer than those that occur in individuals with hypokalemic periodic paralysis. Electrical myotonia is evident in 50% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. The cardiac and <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> features of ATS are absent. Molecular testing reveals pathogenic variants in <i>SCN4A</i> in approximately 80% of individuals. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>. Secondary forms of hyperkalemic periodic paralysis to rule out include adrenal insufficiency, hypoaldosteronism, and adverse effects of certain medications (e.g., ACE inhibitors, spironolactone, nonsteroidal anti-inflammatory drugs).</p><p><b>Thyrotoxic periodic paralysis</b> (OMIM <a href="http://omim.org/entry/188580" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">188580</a>, <a href="http://omim.org/entry/613239" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613239</a>, <a href="http://omim.org/entry/614834" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">614834</a>) is a consideration in any individual with severe weakness and marked hypokalemia. Men, particularly Asians, are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> in greater numbers; however, thyrotoxic periodic paralysis may be seen in individuals of all ethnicities. Diagnosis is established by measurement of serum thyroid-stimulating hormone (TSH), T4, and T3 concentrations. In one series a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in an inwardly rectifying potassium (Kir) channel (encoded by <i>KCNJ18</i>) was identified in approximately one third of affected individuals [<a class="bk_pop" href="#acpp.REF.ryan.2010.88">Ryan et al 2010</a>].</p></div><div id="acpp.Long_QT_Syndromes"><h3>Long QT Syndromes</h3><p>See <a href="/books/n/gene/rws/">Long QT Syndrome</a>, a review of similar phenotypes that are genetically diverse.</p></div><div id="acpp.Palpitations_Syncope_or_Cardiac_Arr"><h3>Palpitations, Syncope, or Cardiac Arrest</h3><p>Syncopal episodes are often interpreted as a neurologic problem rather than arrhythmia. Physical examination and ECG should be part of the evaluation of syncope. Bidirectional ventricular tachycardia demonstrated on ECG may be seen with ATS, digitalis toxicity, and <a href="/books/n/gene/cvt/">catecholaminergic polymorphic ventricular tachycardia</a> (CPVT). A normal resting ECG with exercise-induced polymorphic arrhythmias is a clue to CPVT. Pathogenic variants in <i>RYR2</i> or <i>CASQ2</i> are causative. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> [<a class="bk_pop" href="#acpp.REF.tristanifirouzi.2010.289">Tristani-Firouzi &#x00026; Etheridge 2010</a>].</p></div></div><div id="acpp.Management"><h2 id="_acpp_Management_">Management</h2><div id="acpp.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with Andersen-Tawil syndrome (ATS), the evaluations summarized in <a class="figpopup" href="/books/NBK1264/table/acpp.T.recommended_evaluations_following/?report=objectonly" target="object" rid-figpopup="figacppTrecommendedevaluationsfollowing" rid-ob="figobacppTrecommendedevaluationsfollowing">Table 2</a> (if not performed as part of the evaluation that led to the diagnosis) are recommended:</p><div id="acpp.T.recommended_evaluations_following" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis in Individuals with ATS</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1264/table/acpp.T.recommended_evaluations_following/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__acpp.T.recommended_evaluations_following_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_acpp.T.recommended_evaluations_following_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Organ System</th><th id="hd_h_acpp.T.recommended_evaluations_following_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_acpp.T.recommended_evaluations_following_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiovascular</b></td><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Baseline assessment</td><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Performed by cardiologist familiar w/LQT management</td></tr><tr><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">12-lead ECG &#x00026; 24-hour Holter monitor</td></tr><tr><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Serum potassium concentrations</td><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Performed at baseline &#x00026; during attacks of weakness</td></tr><tr><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Baseline assessment</td><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Performed by neurologist familiar w/periodic paralysis</td></tr><tr><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Electrophysiologic studies including long exercise protocol</td></tr><tr><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Dental</b></td><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Baseline assessment for dental abnormalities associated w/ATS</td><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Follow up as needed</td></tr><tr><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Musculoskeletal</b></td><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Baseline assessment &#x00026; to establish care w/orthopedist / spine surgeon if scoliosis identified</td><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Follow up as needed</td></tr><tr><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Miscellaneous/</b><br /><b>Other</b></td><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Serum TSH concentration</td><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Verification that serum TSH concentration is w/in normal limits</td></tr><tr><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Consultation w/clinical geneticist &#x00026;/or genetic counselor</td><td headers="hd_h_acpp.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">LQT = long QT</p></div></dd><dt></dt><dd><div><p class="no_margin">TSH = thyroid-stimulating hormone</p></div></dd></dl></div></div></div></div><div id="acpp.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Management of individuals with ATS requires the coordinated input of a neurologist familiar with the treatment of periodic paralysis and a cardiologist familiar with the treatment of cardiac arrhythmias. To date, no randomized clinical therapeutic trials have been conducted on ATS.</p><p>Management of attacks of episodic weakness depends on the associated serum potassium concentration:</p><ul><li class="half_rhythm"><div>If the serum potassium concentration is low (&#x0003c;3.0 mmol/L), administer oral potassium (20-30 mEq/L) every 15-30 minutes (not to exceed 200 mEq in a 12-hour period) until the serum concentration normalizes often shortens the attack. As dysphagia is almost never a problem during attacks of paralysis, oral potassium replacement is the safest route. If intravenous potassium replacement is needed, a 5% mannitol solution instead of a saline or glucose solution (both of which may exacerbate weakness) is recommended. Close monitoring of serum potassium concentrations and ECG is necessary during potassium replacement therapy in an emergency setting to avoid secondary hyperkalemia.</div></li><li class="half_rhythm"><div>Whether a relative drop in serum potassium within the normal range causes episodic paralysis is not clear. If such cases are suspected, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals can work with their physician to devise an individual potassium replacement regimen, with a goal of maintaining serum potassium levels in the high range of normal.</div></li><li class="half_rhythm"><div>Attacks of weakness when serum potassium concentration is high usually resolve within 60 minutes. Episodes may be shortened by ingesting carbohydrates or continuing mild exercise. Intravenous calcium gluconate is rarely necessary for management in an individual seen in an emergency setting.</div></li></ul><p>Vasovagal syncope in individuals with ATS mandates a careful cardiology assessment [<a class="bk_pop" href="#acpp.REF.airey.2009.1814">Airey et al 2009</a>].</p></div><div id="acpp.Prevention_of_Primary_Manifestation"><h3>Prevention of Primary Manifestations</h3><p>Prophylactic treatment aimed at reduction of attack frequency and severity can be achieved, as in other forms of periodic paralysis, with the following:</p><ul><li class="half_rhythm"><div>Lifestyle and dietary modification to avoid known triggers</div></li><li class="half_rhythm"><div>Use of carbonic anhydrase inhibitors (acetazolamide: adults 125-1,000 mg daily and children 5-10 mg/kg/day divided 1-2x/day or dichlorphenamide 50-200 mg/1-2x/day). Use of potassium-sparing diuretic should be individualized based on patient needs.</div></li><li class="half_rhythm"><div>Daily use of slow-release potassium supplements, which may also be helpful in controlling attack rates in individuals prone to hypokalemia. Elevating the serum potassium concentration (&#x0003e;4 mEq/L) has the added benefit of narrowing the QT interval, thus reducing the risk of LQT-associated arrhythmias.</div></li><li class="half_rhythm"><div>An implantable cardioverter-defibrillator in individuals with tachycardia-induced syncope [<a class="bk_pop" href="#acpp.REF.chun.2004.235">Chun et al 2004</a>]</div></li><li class="half_rhythm"><div>Empiric treatment with flecainide [<a class="bk_pop" href="#acpp.REF.b_kenkamp.2007.508">B&#x000f6;kenkamp et al 2007</a>, <a class="bk_pop" href="#acpp.REF.fox.2008.1006">Fox et al 2008</a>, <a class="bk_pop" href="#acpp.REF.pellizz_n.2008.95">Pellizz&#x000f3;n et al 2008</a>] should be considered for significant, frequent ventricular arrhythmias in the setting of reduced left ventricular function [<a class="bk_pop" href="#acpp.REF.tristanifirouzi.2010.289">Tristani-Firouzi &#x00026; Etheridge 2010</a>]. A prospective open label study in ten individuals with ATS and a confirmed <i>KCNJ2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> tested the effect of flecainide, a type 1c antiarrhythmic, for the prevention of cardiac arrhythmias [<a class="bk_pop" href="#acpp.REF.miyamoto.2015.596">Miyamoto et al 2015</a>]. Outcomes included a 24-hour Holter monitor before and after treatment and a treadmill exercise test. Flecainide was found to significantly reduce the number of ventricular arrhythmias seen on Holter monitor and to suppress exercise-induced ventricular arrhythmias. Individuals were then followed for a mean of 23 months and no syncope or cardiac arrest was documented. Other case studies have reported beneficial effects with flecainide [<a class="bk_pop" href="#acpp.REF.statland.2018.522">Statland et al 2018</a>]. A recent study showed that fleicainide suppresses arrhythmogenicity through Na<sup>+/</sup>Ca<sup>2+</sup> exchanger flux in induced pluripotent stem cells derived from patients with ATS [<a class="bk_pop" href="#acpp.REF.kuroda.2017.245">Kuroda et al 2017</a>]. Thus, flecainide may reduce cardiac arrhythmias in ATS.</div></li></ul></div><div id="acpp.Prevention_of_Secondary_Complicatio"><h3>Prevention of Secondary Complications</h3><p>Cardiologists should be aware that some antiarrhythmic drugs (e.g., lidocaine, mexiletine, propafenone, quinidine), particularly Class I drugs, may paradoxically exacerbate the neuromuscular symptoms and should be used cautiously in individuals with ATS.</p><p>Although <a href="/books/n/gene/mhs/">malignant hyperthermia</a> has not been reported in ATS, appropriate anesthetic precautions should be undertaken, as with individuals with other forms of periodic paralysis.</p></div><div id="acpp.Surveillance"><h3>Surveillance</h3><p>For asymptomatic individuals with a <i>KCNJ2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, annual screening including a 12-lead ECG and 24-hour Holter monitoring is desirable, followed by referral to a cardiologist if abnormalities are identified.</p></div><div id="acpp.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Affected individuals should avoid medications known to prolong QT intervals. See <a href="http://www.crediblemeds.org/everyone/composite-list-all-qtdrugs/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CredibleMeds<sup>&#x000ae;</sup></a> for a complete and updated list.</p><p>Salbutamol inhalers, which may be used in the treatment of primary hyperkalemic periodic paralysis, should be avoided because of the potential for exacerbation of cardiac arrhythmias.</p><p>Thiazide and other potassium-wasting diuretics may provoke drug-induced hypokalemia and could aggravate the QT interval prolongation.</p></div><div id="acpp.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate relatives at risk in order to identify as early as possible those who would benefit from initiation of treatment and preventive measures:</p><ul><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can be used to clarify the genetic status of at-risk relatives.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is not known, detailed neurologic and cardiologic evaluation, 12-lead ECG, and 24-hour Holter monitoring can be used to clarify the disease status of at-risk relatives.</div></li></ul><p>See <a href="#acpp.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="acpp.Pregnancy_Management"><h3>Pregnancy Management</h3><p>The rarity of ATS and the paucity of reports pertaining to pregnancy in women with ATS make an evidence-based approach to pregnancy management difficult to formulate. One case study reported an uneventful pregnancy, with increased episodes of weakness but reduced ventricular ectopy compared to the pre-pregnancy period [<a class="bk_pop" href="#acpp.REF.subbiah.2008.987">Subbiah et al 2008</a>]. However, as data are limited, a multidisciplinary approach to individual care and <a class="def" href="/books/n/gene/glossary/def-item/anticipation/">anticipation</a> of increased risk (as can be seen in those with long QT syndrome) seems reasonable.</p></div><div id="acpp.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="acpp.Genetic_Counseling"><h2 id="_acpp_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="acpp.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Andersen-Tawil syndrome (ATS) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="acpp.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At least 50% of individuals diagnosed with ATS have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with ATS may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>KCNJ2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of cases caused by a <i>de novo</i> pathogenic variant in <i>KCNJ2</i> may be as high as 50%.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include: a detailed neurologic and cardiologic evaluation, 12-lead ECG, 24-hour Holter monitoring, and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the <i>KCNJ2</i> pathogenic variant identified in the proband.</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with ATS may appear to be negative because of failure to recognize the disorder in family members, early death of the parent not attributed to the disease, or reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>. Therefore, an apparently negative family history cannot be confirmed unless appropriate neurologic and cardiologic evaluations and/or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the genetic status of the proband's parents.</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or has the <i>KCNJ2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the proband, the risk to the sibs of inheriting the pathogenic variant is 50%.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a known ATS-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that cannot be detected in the leukocyte DNA of either parent, the <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to sibs is slightly greater than that of the general population because of the possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#acpp.REF.hasegawa.2015.279">Hasegawa et al 2015</a>].</div></li><li class="half_rhythm"><div>If the parents have not been tested for the <i>KCNJ2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> but are clinically unaffected, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> appears to be low. However, sibs of a proband with clinically unaffected parents are still presumed to be at increased risk for ATS because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> parent or the possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#acpp.REF.hasegawa.2015.279">Hasegawa et al 2015</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with ATS has a 50% chance of inheriting the <i>KCNJ2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <i>KCNJ2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the proband, his or her family members are at risk.</p></div><div id="acpp.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#acpp.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with ATS has the pathogenic variant or clinical evidence of the disorder, the <i>KCNJ2</i> pathogenic variant is likely <i>de novo</i>. However, possible non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="acpp.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>KCNJ2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for ATS are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="acpp.Resources"><h2 id="_acpp_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=andersentawilsyndrome" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Andersen-Tawil syndrome</a></div></li><li class="half_rhythm"><div><b>Periodic Paralysis International</b></div><div>Canada</div><div><a href="http://hkpp.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.hkpp.org</a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy Association - USA (MDA)</b></div><div>222 South Riverside Plaza</div><div>Suite 1500</div><div>Chicago IL 60606</div><div><b>Phone:</b> 800-572-1717</div><div><b>Email:</b> mda@mdausa.org</div><div><a href="http://www.mda.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mda.org</a></div></li><li class="half_rhythm"><div><b>Periodic Paralysis Association (PPA)</b></div><div>155 West 68th Street</div><div>Suite 1732</div><div>New York NY 10023</div><div><b>Phone:</b> 407-339-9499</div><div><b>Email:</b> lfeld@cfl.rr.com</div><div><a href="http://www.periodicparalysis.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.periodicparalysis.org</a></div></li><li class="half_rhythm"><div><b>Sudden Arrhythmia Death Syndromes (SADS) Foundation</b></div><div>508 East South Temple</div><div>Suite #202</div><div>Salt Lake City UT 84102</div><div><b>Phone:</b> 800-786-7723 (toll-free); 801-531-0937</div><div><b>Email:</b> sads@sads.org</div><div><a href="http://www.sads.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.sads.org</a></div></li><li class="half_rhythm"><div><b>International Long QT Syndrome Registry</b></div><div>Heart Research Follow-Up Program</div><div>Box 653</div><div>Rochester NY 14642-8653</div><div><b>Phone:</b> 585-276-0016</div><div><b>Fax:</b> 585-273-5283</div><div><b>Email:</b> heartajm@heart.rochester.edu</div></li></ul></div><div id="acpp.Molecular_Genetics"><h2 id="_acpp_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="acpp.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Andersen-Tawil Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1264/table/acpp.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__acpp.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_acpp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_acpp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_acpp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_acpp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_acpp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_acpp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_acpp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3759" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>KCNJ2</i></a></td><td headers="hd_b_acpp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3759" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">17q24<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_acpp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P63252" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Inward rectifier potassium channel 2</a></td><td headers="hd_b_acpp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/KCNJ2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KCNJ2 database</a><br /><a href="https://lovd.nl/KCNJ2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KCNJ2 @ ZAC-GGM</a></td><td headers="hd_b_acpp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=KCNJ2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KCNJ2</a></td><td headers="hd_b_acpp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=KCNJ2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KCNJ2</a></td></tr><tr><td headers="hd_b_acpp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3762" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>KCNJ5</i></a></td><td headers="hd_b_acpp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3762" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">11q24<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_acpp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P48544" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">G protein-activated inward rectifier potassium channel 4</a></td><td headers="hd_b_acpp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/KCNJ5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KCNJ5 database</a></td><td headers="hd_b_acpp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=KCNJ5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KCNJ5</a></td><td headers="hd_b_acpp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=KCNJ5[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KCNJ5</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="acpp.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="acpp.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Andersen-Tawil Syndrome (<a href="/omim/170390,600681,600734" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1264/table/acpp.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__acpp.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/170390" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">170390</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ANDERSEN CARDIODYSRHYTHMIC PERIODIC PARALYSIS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/600681" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600681</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 2; KCNJ2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/600734" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600734</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 5; KCNJ5</td></tr></tbody></table></div></div><p><b><i>KCNJ2</i></b></p><p><b>Gene structure.</b>
<i>KCNJ2</i> has two exons spanning 5.4 kb. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1264/#acpp.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> See <a href="/books/NBK1264/#acpp.molgen.TA">Table A</a>, <b>Locus-Specific</b>
<b>Databases</b> and <b>HGMD</b>. The p.Arg218Trp <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is considered a potential mutational <a class="def" href="/books/n/gene/glossary/def-item/hot-spot/">hot spot</a> [<a class="bk_pop" href="#acpp.REF.davies.2005.1083">Davies et al 2005</a>]. The majority of pathogenic variants in <i>KCNJ2</i> are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> changes. A small number of <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> deletions and a <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> have also been reported.</p><div id="acpp.T.kcnj2_pathogenic_variants_discuss" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>KCNJ2</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1264/table/acpp.T.kcnj2_pathogenic_variants_discuss/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__acpp.T.kcnj2_pathogenic_variants_discuss_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.199C&#x0003e;T</td><td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg67Trp&#x000a0;<sup>1</sup></td><td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_3" rowspan="7" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000891.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000891<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_000882.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000882<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.271_282del12</td><td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala91_Leu94del&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.652C&#x0003e;T</td><td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg218Trp&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.665T&#x0003e;C</td><td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu222Ser&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.899G&#x0003e;A</td><td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly300Asp&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.953A&#x0003e;G</td><td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn318Ser&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.966G&#x0003e;C</td><td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp322Cys&#x000a0;<sup>1</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="acpp.TF.3.1"><p class="no_margin">See <a href="#acpp.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</p></div></dd><dt>2. </dt><dd><div id="acpp.TF.3.2"><p class="no_margin">See <a href="#acpp.Clinical_Description">Clinical Description</a>.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>KCNJ2</i> encodes the inward rectifier potassium channel 2 protein (Kir2.1), with 427 amino acid residues and 48-kd molecular weight. Kir2.1 is expressed primarily in skeletal muscle, heart, and brain. Kir2.1 is involved in setting and stabilizing the resting membrane potential in skeletal and cardiac muscle and has a major role in the terminal repolarization phase of the cardiac action potential [<a class="bk_pop" href="#acpp.REF.plaster.2001.511">Plaster et al 2001</a>, <a class="bk_pop" href="#acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in <i>KCNJ2</i> cause <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> suppression of Kir2.1 current [<a class="bk_pop" href="#acpp.REF.plaster.2001.511">Plaster et al 2001</a>, <a class="bk_pop" href="#acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</a>, <a class="bk_pop" href="#acpp.REF.lange.2003.321">Lange et al 2003</a>, <a class="bk_pop" href="#acpp.REF.donaldson.2004.92">Donaldson et al 2004</a>, <a class="bk_pop" href="#acpp.REF.davies.2005.1083">Davies et al 2005</a>, <a class="bk_pop" href="#acpp.REF.ballester.2006.388">Ballester et al 2006</a>, <a class="bk_pop" href="#acpp.REF.barajasmartinez.2011.51">Barajas-Martinez et al 2011</a>, <a class="bk_pop" href="#acpp.REF.marrus.2011.500">Marrus et al 2011</a>] and affect channel-PIP<sub>2</sub> interactions [<a class="bk_pop" href="#acpp.REF.donaldson.2003.1811">Donaldson et al 2003</a>]. Several pathogenic variants affect trafficking of the mutant channel to the cell surface for reasons that are not clear [<a class="bk_pop" href="#acpp.REF.ballester.2006.388">Ballester et al 2006</a>]. One study identified loss of an endoplasmic reticulum export motif [<a class="bk_pop" href="#acpp.REF.doi.2011.253">Doi et al 2011</a>]. The majority traffic normally to the cell surface but fail to conduct normally [<a class="bk_pop" href="#acpp.REF.bendahhou.2003.51779">Bendahhou et al 2003</a>]. Phosphatidylinositol 4,5 bisphosphate (PIP<sub>2</sub>) is an important regulator of Kir2.1 channel function; many <i>KCNJ2</i> pathogenic variants alter PIP<sub>2</sub> binding [<a class="bk_pop" href="#acpp.REF.lopes.2002.933">Lopes et al 2002</a>, <a class="bk_pop" href="#acpp.REF.donaldson.2003.1811">Donaldson et al 2003</a>].</p><p>Flaccid paralysis results from failure to propagate action potentials in the muscle membrane as a result of sustained membrane depolarization [<a class="bk_pop" href="#acpp.REF.cannon.2002.533">Cannon 2002</a>]. The modestly prolonged QT interval and ventricular arrhythmias are caused by impaired cardiac ventricular repolarization; the reduced inward rectifying potassium current results in distinct T-U wave morphology [<a class="bk_pop" href="#acpp.REF.tristanifirouzi.2001.50">Tristani-Firouzi et al 2001</a>, <a class="bk_pop" href="#acpp.REF.zhang.2005.2720">Zhang et al 2005</a>].</p><p>While the role of Kir2.1 in skeletal development remains to be clarified, consistent craniofacial, dental, and skeletal anomalies are present [<a class="bk_pop" href="#acpp.REF.yoon.2006a.312">Yoon et al 2006a</a>].</p><p>Targeted disruption of Kir2.1 in a knockout mouse is fatal, with complete cleft of the secondary palate [<a class="bk_pop" href="#acpp.REF.zaritsky.2000.160">Zaritsky et al 2000</a>].</p><p><b><i>KCNJ5</i></b></p><p><b>Pathogenic variants.</b> One individual with clinical criteria of ATS and a novel <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KCNJ5</i> (p.Gly387Arg) has been described. The <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> had periodic paralysis and ventricular arrhythmias, with a family history of ventricular arrhythmias on his father's side. A review of 21 individuals in a Japanese cohort (in whom ATS was suspected but a <i>KCNJ2</i> pathogenic variant was not found) identified one additional individual with a novel variant in <i>KCNJ5</i> (p.Thr158Ala) [<a class="bk_pop" href="#acpp.REF.kokunai.2014.1058">Kokunai et al 2014</a>]. The ultimate frequency of <i>KCNJ5</i> pathogenic variants in individuals who meet clinical criteria for ATS but do not have a <i>KCNJ2</i> variant remains to be determined.</p><div id="acpp.T.kcnj5_pathogenic_variants_discuss" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p><i>KCNJ5</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1264/table/acpp.T.kcnj5_pathogenic_variants_discuss/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__acpp.T.kcnj5_pathogenic_variants_discuss_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_acpp.T.kcnj5_pathogenic_variants_discuss_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_acpp.T.kcnj5_pathogenic_variants_discuss_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_acpp.T.kcnj5_pathogenic_variants_discuss_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_acpp.T.kcnj5_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.472A&#x0003e;G</td><td headers="hd_h_acpp.T.kcnj5_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr158Ala&#x000a0;<sup>1</sup></td><td headers="hd_h_acpp.T.kcnj5_pathogenic_variants_discuss_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000890.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000890<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_000881.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000881<wbr style="display:inline-block"></wbr>​.3</a></td></tr><tr><td headers="hd_h_acpp.T.kcnj5_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1159G&#x0003e;C</td><td headers="hd_h_acpp.T.kcnj5_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly387Arg&#x000a0;<sup>1</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="acpp.TF.4.1"><p class="no_margin">See <a class="figpopup" href="/books/NBK1264/table/acpp.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figacppTmoleculargenetictestingusedin" rid-ob="figobacppTmoleculargenetictestingusedin">Table 1</a>.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>KCNJ5</i> codes a 419-amino-acid G protein-activated inwardly rectifying potassium channel protein 4 (Kir3.4). Expression studies show that <i>KCNJ5</i> is expressed in cardiac and skeletal muscle.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Functional studies on the p.Gly387Arg <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KCNJ5</i> also demonstrated a <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> effect on Kir2.1 function [<a class="bk_pop" href="#acpp.REF.kokunai.2014.1058">Kokunai et al 2014</a>].</p></div><div id="acpp.References"><h2 id="_acpp_References_">References</h2><div id="acpp.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.ai.2002.2592">Ai T, Fujiwara Y, Tsuji K, Otani H, Nakano S, Kubo Y, Horie M. Novel KCNJ2 mutation in familial periodic paralysis with ventricular dysrhythmia. <span><span class="ref-journal">Circulation. </span>2002;<span class="ref-vol">105</span>:2592–4.</span> [<a href="/pubmed/12045162" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12045162</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.airey.2009.1814">Airey KJ, Etheridge SP, Tawil R, Tristani-Firouzi M. Resuscitated sudden cardiac death in Andersen-Tawil syndrome. <span><span class="ref-journal">Heart Rhythm. </span>2009;<span class="ref-vol">6</span>:1814–7.</span> [<a href="/pmc/articles/PMC2789273/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2789273</span></a>] [<a href="/pubmed/19959136" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19959136</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.andelfinger.2002.663">Andelfinger G, Tapper AR, Welch RC, Vanoye CG, George AL Jr, Benson DW. KCNJ2 mutation results in Andersen syndrome with sex-specific cardiac and skeletal muscle phenotypes. <span><span class="ref-journal">Am J Hum Genet. </span>2002;<span class="ref-vol">71</span>:663–8.</span> [<a href="/pmc/articles/PMC379203/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC379203</span></a>] [<a href="/pubmed/12148092" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12148092</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.andersen.1971.559">Andersen ED, Krasilnikoff PA, Overvad H. Intermittent muscular weakness, extrasystoles, and multiple developmental anomalies. A new syndrome? <span><span class="ref-journal">Acta Paediatr Scand. </span>1971;<span class="ref-vol">60</span>:559–64.</span> [<a href="/pubmed/4106724" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4106724</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.ballester.2006.388">Ballester LY, Benson DW, Wong B, Law IH, Mathews KD, Vanoye CG, George AL Jr. Trafficking-competent and trafficking-defective KCNJ2 mutations in Andersen syndrome. <span><span class="ref-journal">Hum Mutat. </span>2006;<span class="ref-vol">27</span>:388.</span> [<a href="/pubmed/16541386" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16541386</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.barajasmartinez.2011.51">Barajas-Martinez H, Hu D, Ontiveros G, Caceres G, Desai M, Burashnikov E, Scaglione J, Antzelevitch C. Biophysical and molecular characterization of a novel de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry. <span><span class="ref-journal">Circ Cardiovasc Genet. </span>2011;<span class="ref-vol">4</span>:51–7.</span> [<a href="/pmc/articles/PMC3041844/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3041844</span></a>] [<a href="/pubmed/21148745" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21148745</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.bendahhou.2003.51779">Bendahhou S, Donaldson MR, Plaster NM, Tristani-Firouzi M, Fu YH, Pt&#x000e1;cek LJ. Defective potassium channel Kir2.1 trafficking underlies Andersen-Tawil syndrome. <span><span class="ref-journal">J Biol Chem. </span>2003;<span class="ref-vol">278</span>:51779–85.</span> [<a href="/pubmed/14522976" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14522976</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.b_kenkamp.2007.508">B&#x000f6;kenkamp R, Wilde AA, Schalij MJ, Blom NA. Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome. <span><span class="ref-journal">Heart Rhythm. </span>2007;<span class="ref-vol">4</span>:508–11.</span> [<a href="/pubmed/17399642" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17399642</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.cannon.2002.533">Cannon SC. An expanding view for the molecular basis of familial periodic paralysis. <span><span class="ref-journal">Neuromuscul Disord. </span>2002;<span class="ref-vol">12</span>:533–43.</span> [<a href="/pubmed/12117476" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12117476</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.chun.2004.235">Chun TU, Epstein MR, Dick M 2nd, Andelfinger G, Ballester L, Vanoye CG, George AL Jr, Benson DW. Polymorphic ventricular tachycardia and KCNJ2 mutations. <span><span class="ref-journal">Heart Rhythm. </span>2004;<span class="ref-vol">1</span>:235–41.</span> [<a href="/pubmed/15851159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15851159</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.davies.2005.1083">Davies NP, Imbrici P, Fialho D, Herd C, Bilsland LG, Weber A, Mueller R, Hilton-Jones D, Ealing J, Boothman BR, Giunti P, Parsons LM, Thomas M, Manzur AY, Jurkat-Rott K, Lehmann-Horn F, Chinnery PF, Rose M, Kullmann DM, Hanna MG. Andersen-Tawil syndrome: new potassium channel mutations and possible phenotypic variation. <span><span class="ref-journal">Neurology. </span>2005;<span class="ref-vol">65</span>:1083–9.</span> [<a href="/pubmed/16217063" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16217063</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.delannoy.2013.1805">Delannoy E, Sacher F, Maury P, Mabo P, Mansourati J, Magnin I, Camous JP, Tournant G, Rendu E, Kyndt F, Ha&#x000ef;ssaguerre M, B&#x000e9;zieau S, Guyomarch B, Le Marec H, Fressart V, Denjoy I, Probst V. Cardiac characteristics and long-term outcome in Andersen-Tawil syndrome patients related to KCNJ2 mutation. <span><span class="ref-journal">Europace. </span>2013;<span class="ref-vol">15</span>:1805–11.</span> [<a href="/pubmed/23867365" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23867365</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.doi.2011.253">Doi T, Makiyama T, Morimoto T, Haruna Y, Tsuji K, Ohno S, Akao M, Takahashi Y, Kimura T, Horie M. A novel KCNJ2 nonsense mutation, S369X, impedes trafficking and causes a limited form of Andersen-Tawil syndrome. <span><span class="ref-journal">Circ Cardiovasc Genet. </span>2011;<span class="ref-vol">4</span>:253–60.</span> [<a href="/pubmed/21493816" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21493816</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.donaldson.2003.1811">Donaldson MR, Jensen JL, Tristani-Firouzi M, Tawil R, Bendahhou S, Suarez WA, Cobo AM, Poza JJ, Behr E, Wagstaff J, Szepetowski P, Pereira S, Mozaffar T, Escolar DM, Fu YH, Pt&#x000e1;cek LJ. PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome. <span><span class="ref-journal">Neurology. </span>2003;<span class="ref-vol">60</span>:1811–6.</span> [<a href="/pubmed/12796536" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12796536</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.donaldson.2004.92">Donaldson MR, Yoon G, Fu YH, Ptacek LJ. Andersen-Tawil syndrome: a model of clinical variability, pleiotropy, and genetic heterogeneity. <span><span class="ref-journal">Ann Med. </span>2004;<span class="ref-vol">36</span> Suppl 1:92–7.</span> [<a href="/pubmed/15176430" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15176430</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.fernlund.2013.471">Fernlund E, Lundin C, Hertervig E, Kongstad O, Alders M, Platonov P. Novel mutation in the KCNJ2 gene is associated with a malignant arrhythmic phenotype of Andersen-Tawil syndrome. <span><span class="ref-journal">Ann Noninvasive Electrocardiol. </span>2013;<span class="ref-vol">18</span>:471–8.</span> [<a href="/pubmed/24047492" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24047492</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.fournier.2004.650">Fournier E, Arzel M, Sternberg D, Vicart S, Laforet P, Eymard B, Willer JC, Tabti N, Fontaine B. Electromyography guides toward subgroups of mutations in muscle channelopathies. <span><span class="ref-journal">Ann Neurol. </span>2004;<span class="ref-vol">56</span>:650–61.</span> [<a href="/pubmed/15389891" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15389891</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.fox.2008.1006">Fox DJ, Klein GJ, Hahn A, Skanes AC, Gula LJ, Yee RK, Subbiah RN, Krahn AD. Reduction of complex ventricular ectopy and improvement in exercise capacity with flecainide therapy in Andersen-Tawil syndrome. <span><span class="ref-journal">Europace. </span>2008;<span class="ref-vol">10</span>:1006–8.</span> [<a href="/pubmed/18621769" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18621769</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.haruna.2007.208">Haruna Y, Kobori A, Makiyama T, Yoshida H, Akao M, Doi T, Tsuji K, Ono S, Nishio Y, Shimizu W, Inoue T, Murakami T, Tsuboi N, Yamanouchi H, Ushinohama H, Nakamura Y, Yoshinaga M, Horigome H, Aizawa Y, Kita T, Horie M. Genotype-phenotype correlations of KCNJ2 mutations in Japanese patients with Andersen-Tawil syndrome. <span><span class="ref-journal">Hum Mutat. </span>2007;<span class="ref-vol">28</span>:208.</span> [<a href="/pubmed/17221872" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17221872</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.hasegawa.2015.279">Hasegawa K, Ohno S, Kimura H, Itoh H, Makiyama T, Yoshida Y, Horie M. Mosaic KCNJ2 mutation in Andersen-Tawil syndrome: targeted deep sequencing is useful for the detection of mosaicism. <span><span class="ref-journal">Clin Genet. </span>2015;<span class="ref-vol">87</span>:279–83.</span> [<a href="/pubmed/24635491" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24635491</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.horga.2013.1472">Horga A, Raja Rayan DL, Matthews E, Sud R, Fialho D, Durran SC, Burge JA, Portaro S, Davis MB, Haworth A, Hanna MG. Prevalence study of genetically defined skeletal muscle channelopathies in England. <span><span class="ref-journal">Neurology. </span>2013;<span class="ref-vol">80</span>:1472–5.</span> [<a href="/pmc/articles/PMC3662361/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3662361</span></a>] [<a href="/pubmed/23516313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23516313</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.hosaka.2003.409">Hosaka Y, Hanawa H, Washizuka T, Chinushi M, Yamashita F, Yoshida T, Komura S, Watanabe H, Aizawa Y. Function, subcellular localization and assembly of a novel mutation of KCNJ2 in Andersen's syndrome. <span><span class="ref-journal">J Mol Cell Cardiol. </span>2003;<span class="ref-vol">35</span>:409–15.</span> [<a href="/pubmed/12689820" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12689820</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.katz.1999.352">Katz JS, Wolfe GI, Iannaccone S, Bryan WW, Barohn RJ. The exercise test in Andersen syndrome. <span><span class="ref-journal">Arch Neurol. </span>1999;<span class="ref-vol">56</span>:352–6.</span> [<a href="/pubmed/10190827" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10190827</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.kim.2016.110">Kim NR, Jang J, Jean GW, Cho E, Sin JB. Identification of the KCNJ2 mutation in a Korean family with Andersen-Tawil syndrome and developmental delay. <span><span class="ref-journal">Ann Clin Lab Sci. </span>2016;<span class="ref-vol">46</span>:110–3.</span> [<a href="/pubmed/26927354" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26927354</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.kimura.2012.344">Kimura H, Zhou J, Kawamura M, Itoh H, Mizusawa Y, Ding WG, Wu J, Ohno S, Makiyama T, Miyamoto A, Naiki N, Wang Q, Xie Y, Suzuki T, Tateno S, Nakamura Y, Zang WJ, Ito M, Matsuura H, Horie M. Phenotype variability in patients carrying KCNJ2 mutations. <span><span class="ref-journal">Circ Cardiovasc Genet. </span>2012;<span class="ref-vol">5</span>:344–53.</span> [<a href="/pubmed/22589293" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22589293</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.kokunai.2014.1058">Kokunai Y, Nakata T, Furuta M, Sakata S, Kimura H, Aiba T, Yoshinaga M, Osaki Y, Nakamori M, Itoh H, Sato T, Kubota T, Kadota K, Shindo K, Mochizuki H, Shimizu W, Horie M, Okamura Y, Ohno K, Takahashi MP. A Kir3.4 mutation causes Andersen-Tawil syndrome by an inhibitory effect on Kir2.1. <span><span class="ref-journal">Neurology. </span>2014;<span class="ref-vol">82</span>:1058–64.</span> [<a href="/pubmed/24574546" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24574546</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.koppikar.2015.1493">Koppikar S, Barbosa-Barros R, Baranchuk A. A practical approach to the investigation of an rSr' pattern in leads V1-V2. <span><span class="ref-journal">Can J Cardiol. </span>2015;<span class="ref-vol">31</span>:1493–6.</span> [<a href="/pubmed/26143139" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26143139</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.krych.2017.504">Krych M, Biernacka EK, Poninska J, Kukla P, Filipecki A, Gajda R, Hasdemir C, Antzelevitch C, Kosiec A, Malgorzata S, Ploski R, Trusz-Gluza M, Mizia-Stec K, Hoffman P. Andersen-Tawil syndrome: Clinical presentation and predictors of symptomatic arrhythmias - possible role of polymorphisms K897T in KCNH2 and H558R in SCN5A gene. <span><span class="ref-journal">Journal of Cardiology. </span>2017;<span class="ref-vol">70</span>:504–10.</span> [<a href="/pmc/articles/PMC5607087/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5607087</span></a>] [<a href="/pubmed/28336205" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28336205</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.kuntzer.2000.1089">Kuntzer T, Flocard F, Vial C, Kohler A, Magistris M, Labarre-Vila A, Gonnaud PM, Ochsner F, Soichot P, Chan V, Monnier G. Exercise test in muscle channelopathies and other muscle disorders. <span><span class="ref-journal">Muscle Nerve. </span>2000;<span class="ref-vol">23</span>:1089–94.</span> [<a href="/pubmed/10883004" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10883004</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.kuroda.2017.245">Kuroda Y, Yuasa S, Watanabe Y, Ito S, Egashira T, Seki T, Hattori T, Ohno S, Kodaira M, Suzuki T, Hashimoto H, Okata S, Tanaka A, Aizawa Y, Murata M, Aiba T, Makita N, Furukawa T, Shimizu W, Kodama I, Ogawa S, Kokubun N, Horigome H, Horie M, Kamiya K, Fukuda K. Flecainide ameliorates arrhythmogenicity through NCX flux in Andersen-Tawil syndrome-iPS cell-derived cardiomyocytes. <span><span class="ref-journal">Biochem Biophys Rep. </span>2017;<span class="ref-vol">9</span>:245–56.</span> [<a href="/pmc/articles/PMC5614591/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5614591</span></a>] [<a href="/pubmed/28956012" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28956012</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.lange.2003.321">Lange PS, Er F, Gassanov N, Hoppe UC. Andersen mutations of KCNJ2 suppress the native inward rectifier current IK1 in a dominant-negative fashion. <span><span class="ref-journal">Cardiovasc Res. </span>2003;<span class="ref-vol">59</span>:321–7.</span> [<a href="/pubmed/12909315" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12909315</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.lestner.2012.700">Lestner JM, Ellis R, Canham N. Delineating the 17q24.2-q24.3 microdeletion syndrome phenotype. <span><span class="ref-journal">Eur J Med Genet. </span>2012;<span class="ref-vol">55</span>:700–4.</span> [<a href="/pubmed/22982078" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22982078</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.limberg.2013.353">Limberg MM, Zumhagen S, Netter MF, Coffey AJ, Grace A, Rogers J, B&#x000f6;ckelmann D, Rinn&#x000e9; S, Stallmeyer B, Decher N, Schulze-Bahr E. Non dominant-negative KCNJ2 gene mutations leading to Andersen-Tawil syndrome with an isolated cardiac phenotype. <span><span class="ref-journal">Basic Res Cardiol. </span>2013;<span class="ref-vol">108</span>:353.</span> [<a href="/pubmed/23644778" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23644778</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.lopes.2002.933">Lopes CM, Zhang H, Rohacs T, Jin T, Yang J, Logothetis DE. Alterations in conserved Kir channel-PIP2 interactions underlie channelopathies. <span><span class="ref-journal">Neuron. </span>2002;<span class="ref-vol">34</span>:933–44.</span> [<a href="/pubmed/12086641" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12086641</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.marquisnicholson.2014.17">Marquis-Nicholson R, Prosser DO, Love JM, Zhang L, Hayes I, George AM, Crawford JR, Skinner JR, Love DR. Array comparative genomic hybridization identifies a heterozygous deletion of the entire KCNJ2 gene as a cause of sudden cardiac death. <span><span class="ref-journal">Circ Cardiovasc Genet. </span>2014;<span class="ref-vol">7</span>:17–22.</span> [<a href="/pubmed/24395924" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24395924</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.marrus.2011.500">Marrus SB, Cuculich PS, Wang W, Nerbonne JM. Characterization of a novel, dominant negative KCNJ2 mutation associated with Andersen-Tawil syndrome. <span><span class="ref-journal">Channels (Austin). </span>2011;<span class="ref-vol">5</span>:500–9.</span> [<a href="/pmc/articles/PMC3265798/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3265798</span></a>] [<a href="/pubmed/22186697" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22186697</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.miyamoto.2015.596">Miyamoto K, Aiba T, Kimura H, Hayashi H, Ohno S, Yasuoka C, Tanioka Y, Tsuchiya T, Yoshida Y, Hayashi H, Tsuboi I, Nakajima I, Ishibashi K, Okamura H, Noda T, Ishihara M, Anzai T, Yasuda S, Miyamoto Y, Kamakura S, Kusano K, Ogawa H, Horie M, Shimizu W. Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations. <span><span class="ref-journal">Heart Rhythm. </span>2015;<span class="ref-vol">12</span>:596–603.</span> [<a href="/pubmed/25496985" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25496985</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.pellizz_n.2008.95">Pellizz&#x000f3;n OA, Kalaizich L, Pt&#x000e1;cek LJ, Tristani-Firouzi M, Gonzalez MD. Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome. <span><span class="ref-journal">J Cardiovasc Electrophysiol. </span>2008;<span class="ref-vol">19</span>:95–7.</span> [<a href="/pubmed/17655675" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17655675</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.plaster.2001.511">Plaster NM, Tawil R, Tristani-Firouzi M, Can&#x000fa;n S, Bendahhou S, Tsunoda A, Donaldson MR, Iannaccone ST, Brunt E, Barohn R, Clark J, Deymeer F, George AL Jr, Fish FA, Hahn A, Nitu A, Ozdemir C, Serdaroglu P, Subramony SH, Wolfe G, Fu YH, Pt&#x000e1;cek LJ. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. <span><span class="ref-journal">Cell. </span>2001;<span class="ref-vol">105</span>:511–9.</span> [<a href="/pubmed/11371347" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11371347</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.rezazadeh.2016.1576.e15">Rezazadeh S, Guo J, Duff HJ, Ferrier RA, Gerull B. Reversible dilated cardiomyopathy caused by a high burden of ventricular arrhythmias in Andersen-Tawil syndrome. <span><span class="ref-journal">Can J Cardiol. </span>2016;<span class="ref-vol">32</span>:1576.e15–e18.</span> [<a href="/pubmed/27789106" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27789106</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.ryan.2010.88">Ryan DP, da Silva MR, Soong TW, Fontaine B, Donaldson MR, Kung AW, Jongjaroenprasert W, Liang MC, Khoo DH, Cheah JS, Ho SC, Bernstein HS, Maciel RM, Brown RH Jr, Pt&#x000e1;cek LJ. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. <span><span class="ref-journal">Cell. </span>2010;<span class="ref-vol">140</span>:88–98.</span> [<a href="/pmc/articles/PMC2885139/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2885139</span></a>] [<a href="/pubmed/20074522" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20074522</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.sansone.2007.233">Sansone V, Tawil R. Management and treatment of Andersen-Tawil syndrome. <span><span class="ref-journal">Neurotherapeutics. </span>2007;<span class="ref-vol">4</span>:233–7.</span> [<a href="/pubmed/17395133" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17395133</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.schoonderwoerd.2006.1346">Schoonderwoerd BA, Wiesfeld AC, Wilde AA, van den Heuvel F, Van Tintelen JP, van den Berg MP, Van Veldhuisen DJ, Van Gelder IC. A family with Andersen-Tawil syndrome and dilated cardiomyopathy. <span><span class="ref-journal">Heart Rhythm. </span>2006;<span class="ref-vol">3</span>:1346–50.</span> [<a href="/pubmed/17074642" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17074642</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.statland.2018.522">Statland JM, Fontaine B, Hanna MG, Johnson NE, Kissel JT, Sansone VA, Shieh PB, Tawil RN, Trivedi J, Cannon SC, Griggs RC. Review of the diagnosis and treatment of periodic paralysis. <span><span class="ref-journal">Muscle and Nerve. </span>2018;<span class="ref-vol">57</span>:522–30.</span> [<a href="/pmc/articles/PMC5867231/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5867231</span></a>] [<a href="/pubmed/29125635" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29125635</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.stunnenberg.2018.402">Stunnenberg BC, Raaphorst J, Deenen JCW, Links TP, Wilde AA, Verbove DJ, Kamsteeg EJ, van den Wijngaard A, Faber CG, van der Wilt GJ, van Engelen BGM, Drost G, Ginjaar HB. Prevalence and mutation spectrum of skeletal muscle channelopathies in the Netherlands. <span><span class="ref-journal">Neuromuscul Disord. </span>2018;<span class="ref-vol">28</span>:402–7.</span> [<a href="/pubmed/29606556" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29606556</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.subbiah.2008.987">Subbiah RN, Gula LJ, Skanes AC, Krahn AD. Andersen-Tawil syndrome: management challenges during pregnancy, labor, and delivery. <span><span class="ref-journal">J Cardiovasc Electrophysiol. </span>2008;<span class="ref-vol">19</span>:987–9.</span> [<a href="/pubmed/18554214" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18554214</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.tan.2011.328">Tan SV, Matthews E, Barber M, Burge JA, Rajakulendran S, Fialho D, Sud R, Haworth A, Koltzenburg M, Hanna MG. Refined exercise testing can aid DNA-based diagnosis in muscle channelopathies. <span><span class="ref-journal">Ann Neurol. </span>2011;<span class="ref-vol">69</span>:328–40.</span> [<a href="/pmc/articles/PMC3051421/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3051421</span></a>] [<a href="/pubmed/21387378" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21387378</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.tawil.1994.326">Tawil R, Ptacek LJ, Pavlakis SG, DeVivo DC, Penn AS, Ozdemir C, Griggs RC. Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. <span><span class="ref-journal">Ann Neurol. </span>1994;<span class="ref-vol">35</span>:326–30.</span> [<a href="/pubmed/8080508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8080508</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.tristanifirouzi.2001.50">Tristani-Firouzi M, Chen J, Mitcheson JS, Sanguinetti MC. Molecular biology of K(+) channels and their role in cardiac arrhythmias. <span><span class="ref-journal">Am J Med. </span>2001;<span class="ref-vol">110</span>:50–9.</span> [<a href="/pubmed/11152866" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11152866</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.tristanifirouzi.2010.289">Tristani-Firouzi M, Etheridge SP. Kir 2.1 channelopathies: the Andersen-Tawil syndrome. <span><span class="ref-journal">Pflugers Arch. </span>2010;<span class="ref-vol">460</span>:289–94.</span> [<a href="/pubmed/20306271" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20306271</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi M, Jensen JL, Donaldson MR, Sansone V, Meola G, Hahn A, Bendahhou S, Kwiecinski H, Fidzianska A, Plaster N, Fu YH, Ptacek LJ, Tawil R. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). <span><span class="ref-journal">J Clin Invest. </span>2002;<span class="ref-vol">110</span>:381–8.</span> [<a href="/pmc/articles/PMC151085/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC151085</span></a>] [<a href="/pubmed/12163457" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12163457</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.vergult.2012.534">Vergult S, Dauber A, Delle Chiaie B, Van Oudenhove E, Simon M, Rihani A, Loeys B, Hirschhorn J, Pfotenhauer J, Phillips JA 3rd, Mohammed S, Ogilvie C, Crolla J, Mortier G, Menten B. 17q24.2 microdeletions: a new syndromal entity with intellectual disability, truncal obesity, mood swings and hallucinations. <span><span class="ref-journal">Eur J Hum Genet. </span>2012;<span class="ref-vol">20</span>:534–9.</span> [<a href="/pmc/articles/PMC3330218/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3330218</span></a>] [<a href="/pubmed/22166941" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22166941</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.yoon.2006a.312">Yoon G, Oberoi S, Tristani-Firouzi M, Etheridge SP, Quitania L, Kramer JH, Miller BL, Fu YH, Pt&#x000e1;cek LJ. Andersen-Tawil syndrome: prospective cohort analysis and expansion of the phenotype. <span><span class="ref-journal">Am J Med Genet A. </span>2006a;<span class="ref-vol">140</span>:312–21.</span> [<a href="/pubmed/16419128" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16419128</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.yoon.2006b.1703">Yoon G, Quitania L, Kramer JH, Fu YH, Miller BL, Pt&#x000e1;cek LJ. Andersen-Tawil syndrome: definition of a neurocognitive phenotype. <span><span class="ref-journal">Neurology. </span>2006b;<span class="ref-vol">66</span>:1703–10.</span> [<a href="/pubmed/16769944" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16769944</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.zaritsky.2000.160">Zaritsky JJ, Eckman DM, Wellman GC, Nelson MT, Schwarz TL. Targeted disruption of Kir2.1 and Kir2.2 genes reveals the essential role of the inwardly rectifying K(+) current in K(+)-mediated vasodilation. <span><span class="ref-journal">Circ Res. </span>2000;<span class="ref-vol">87</span>:160–6.</span> [<a href="/pubmed/10904001" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10904001</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="acpp.REF.zhang.2005.2720">Zhang L, Benson DW, Tristani-Firouzi M, Ptacek LJ, Tawil R, Schwartz PJ, George AL, Horie M, Andelfinger G, Snow GL, Fu YH, Ackerman MJ, Vincent GM. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype. <span><span class="ref-journal">Circulation. </span>2005;<span class="ref-vol">111</span>:2720–6.</span> [<a href="/pubmed/15911703" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15911703</span></a>]</div></li></ul></div></div><div id="acpp.Chapter_Notes"><h2 id="_acpp_Chapter_Notes_">Chapter Notes</h2><div id="acpp.Acknowledgments"><h3>Acknowledgments</h3><p>The authors are funded in part by the Consortium for Clinical Investigation of Neurological Channelopathies (CINCH) supported by NIH 8 U54 NS59065 (NINDS/ORD).</p></div><div id="acpp.Author_History"><h3>Author History</h3><p>Jeffrey M Statland, MD (2013-present)<br />Rabi Tawil, MD (2004-present)<br />Aravindhan Veerapandiyan, MBBS (2018-present)<br />Shannon L Venance, MD, PhD; University of Western Ontario (2004-2018)</p></div><div id="acpp.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>7 June 2018 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 September 2015 (rt) Revision: <a href="#acpp.Treatment_of_Manifestations">Treatment of Manifestations</a></div></li><li class="half_rhythm"><div>6 August 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 January 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>13 May 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 March 2007 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>27 April 2005 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> available</div></li><li class="half_rhythm"><div>22 November 2004 (me) Review posted live</div></li><li class="half_rhythm"><div>1 June 2004 (rt) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1264</span><span class="label">PMID: <a href="/pubmed/20301441" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301441</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/als-overview/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/androgen/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1264&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1264/?report=reader">PubReader</a></li><li><a href="/books/NBK1264/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1264" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1264" style="display:none" title="Cite this Page"><div class="bk_tt">Veerapandiyan A, Statland JM, Tawil R. Andersen-Tawil Syndrome. 2004 Nov 22 [Updated 2018 Jun 7]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1264/pdf/Bookshelf_NBK1264.pdf">PDF version of this page</a> (483K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#acpp.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#acpp.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#acpp.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#acpp.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#acpp.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#acpp.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#acpp.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#acpp.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#acpp.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#acpp.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#acpp.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3759[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">KCNJ2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1468160" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1468160" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1468160" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1468160" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301308" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Long QT Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Long QT Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Alders M, Bikker H, Christiaans I. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301669" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hyperkalemic Periodic Paralysis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hyperkalemic Periodic Paralysis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Weber F, Jurkat-Rott K, Lehmann-Horn F. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301512" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hypokalemic Periodic Paralysis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hypokalemic Periodic Paralysis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Weber F, Lehmann-Horn F. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301466" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Catecholaminergic Polymorphic Ventricular Tachycardia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Catecholaminergic Polymorphic Ventricular Tachycardia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Napolitano C, Priori SG, Bloise R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24047492" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Novel mutation in the KCNJ2 gene is associated with a malignant arrhythmic phenotype of Andersen-Tawil syndrome.</a><span class="source">[Ann Noninvasive Electrocardiol...]</span><div class="brieflinkpop offscreen_noflow">Novel mutation in the KCNJ2 gene is associated with a malignant arrhythmic phenotype of Andersen-Tawil syndrome.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Fernlund E, Lundin C, Hertervig E, Kongstad O, Alders M, Platonov P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ann Noninvasive Electrocardiol. 2013 Sep; 18(5):471-8. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301441" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301441" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04294ddd21425a259d3820">Andersen-Tawil Syndrome - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Andersen-Tawil Syndrome - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T22:30:21-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8B7E90E04268310000000001400073&amp;ncbi_session=CE8B7E90E04294C1_0320SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1264%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1264&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1264/&amp;ncbi_pagename=Andersen-Tawil Syndrome - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8B7E90E04294C1_0320SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>